Literature DB >> 23124151

Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.

Nobuyasu Awano1, Minoru Inomata, Keisuke Kondoh, Kohta Satake, Hiroyuki Kamiya, Atsuko Moriya, Tsunehiro Ando, Toshio Kumasaka, Tamiko Takemura, Kengo Takeuchi, Soichiro Ikushima.   

Abstract

Multicentric Castleman's Disease (MCD) is a systemic disease characterized by generalized lymphadenopathy and the proliferation of plasma cells. The development of MCD in a patient with preexisting sarcoidosis has not been previously reported. We herein describe a case of MCD developing in a 78-year-old woman with a 17-year history of sarcoidosis. The patient's serum interleukin-6 (IL-6) levels were only slightly elevated; however, the IL-6 levels in the fluid of both pleural effusion and ascites were markedly elevated. The administration of steroid-pulse therapy and prednisolone was ineffective in treating the MCD, although treatment with tocilizumab proved highly effective.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124151     DOI: 10.2169/internalmedicine.51.8120

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease.

Authors:  Arjun Gupta; Balaji Ayyar; Hamid Zia; Weina Chen; Samar Harris; Harris V Naina
Journal:  Indian J Hematol Blood Transfus       Date:  2015-09-01       Impact factor: 0.900

Review 2.  Refractory Sarcoidosis: A Review.

Authors:  Thomas El Jammal; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Dominique Valeyre; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2020-04-17       Impact factor: 2.423

Review 3.  Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.

Authors:  Gonçalo Boleto; Matheus Vieira; Anne Claire Desbois; David Saadoun; Patrice Cacoub
Journal:  Front Med (Lausanne)       Date:  2020-11-24

4.  Multicentric Castleman's disease developing during follow-up of sarcoidosis.

Authors:  Tetsuro Sawata; Masashi Bando; Masayuki Nakayama; Naoko Mato; Tamiko Takemura; Yukihiko Sugiyama
Journal:  Respirol Case Rep       Date:  2016-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.